You are here

Home » Content

HEMODİYALİZ HASTALARINDA OKSİDAN STRES VE ANTİOKSİDAN SAVUNMA

OXIDANT STRES AND ANTIOXIDANT DEFENCE IN HEMODIALYSIS PATIENTS

Journal Name:

  • Türk Nefroloji, Diyaliz ve Transplantasyon Dergisi

Publication Year:

  • 1997

Key Words:

Keywords (Original Language):

Author NameUniversity of AuthorFaculty of Author
Abstract (2. Language): 
In hemodialysis patients, oxidant stress increases and antioxidant defence decreases. In spite of a lot of factors play a role in this impaired balance, hemodialysis therapy is one of the most important factors. During the hemodialysis therapy, while antioxidant enzymes is increasing, lipid peroxidation may not change. Erythropoietin therapy may effect this system. In this review, possible reasons of increased oxidant stress and decreased antioxidant defence will be discussed.
Bookmark/Search this post with
Abstract (Original Language): 
Hemodiyaliz, hastalarında oksidan stres artmış ve antioksidan savunma azalmıştır. Bu dengenin bozulmasında birçok etken rol oynamakla birlikte hemodiyaliz tedavisi en önemli faktörlerdendir. Hemodiyaliz tedavisi sırasında antioksidan enzimler artarken lipid peroksidasyunu azalmayabilir. Eritropoietin kullanımı bu sistemi etkileyebilir. Bu makalede hemodiyaliz hastalarında artmış oksidan stres ve azalmış antioksidan savunma sebebleri tartışılacaktır.
FULL TEXT (PDF): 
PDF icon pdf_tndt_178.pdf
  • 3-4
102-105
  • Turkish

REFERENCES

References: 

1. Richard M, Arnaud J, Jurkovitz C et al. Trace elements and lipid peroxidation abnormalities in patients with chronic renal failure. Nephron 1991; 57: 10 - 15.
2. Matkovics B, Laszlo A, Varga SZ et al. Changes and correlations of antioxidant enzymes, lipid peroxidation and serum neutral lipids due to haemodialysis treatment in chronic uraemic patients. Int Urol Nephrol 1988; 20(5): 559 - 564.
3. Vanella A, Geremia E, Pinturo R et al. Superoxide dismutase activity and reduced glutathione content in erythrocytes of uremic patients on chronic dialysis. Acta Haemat 1983;70:312-315.
4. Bozfakioğlu S, Alptekin N, Seçkin S et al. Red cell lipid peroxidation and antioxidant system in chronic renal failure patients treated with recombinant human
erythropoietin. Nephron 1992; 61: 228-229.
5. Costagiola C, Romano I, Sorice P et al. Anemia and chronic renal failure: the possible role of the oxidative state of glutathione. Nephron 1989; 52: 11-14.
6. Toigo G, Situlin R, Vasile A et al. Effects of erythropoietin administration on nutritional state and erythrocyte metabolism in maintenance hemodialysis
patients. Contrib Nephrol, Basel, Karger 1992; 98: 79-88.
7. Kuroda M, Asaka S, Tofuku Y et al. Serum antioxidant activity in uremic patients. Nephron 1985; 41: 293 - 298.
8. Chakraborty M, Ghosal J, Biswas T et al. Effect of erythropoietin on membrane lipid peroxidation, superoxide dismutase, catalase and glutathione peroxidase of rat rbc. Biochem Med Metal Biol 1988; 40: 8-18.
9. Koçak N, Toker A, Yalçın S. Erythrocyte lipid peroxidation and glutathione peroxidase activities in patients with chronic renal failure. Med Bull Istanbul
1986; 19:69-74.
10. Seth RK, Saini AS, Aggarwal SK. Glutathione peroxidase activity and reduced glutathione content in erythrocytes of patients with chronic renal failure. Scand J Haematol 1985;35:201-204.
11. Eschbach JW. The anemia of chronic renal failure.
Pathophysiology and the effects of recombinant erythropoietin. Kidney Int 1989; 35: 134-148.
12. Schmidtmann S, Baehr R, Precht K. Free radicals induce increased lysis of red blood cells after haemodialysis.
Nephrol Dial Transplant 1990; 5: 600 - 603.
13. Maher ER, Wickens DG, Griffin JF et al. Increased free radical activity during haemodialysis. Nephrol Dial
Transplant 1987; 2: 169- 171.
104
14. Ichikawa et al. Renal antioxidant enzymes. Kidney Int 1994; 45: 1-9.
15. Naets JP. Hematologic disorders in renal failure. Nephron 1975; 14: 18-194.
16. Eschbach and Adamson. Anemia of end-stage renal disease. Editorial review. Kidney Int 1985; 28: 1-5.
17. Vijoen M, Oliveria A, Milne F. Physical properties of the red blood cells in chronic renal failure. Nephron 1991; 59: 271-278.
18. Rosenmund A, Binswanger U, Straub PW et al. Oxidative injury to erythrocytes, red cells rigidity and splenic hemolysis in hemodialyzed uremic patients. Ann Intern Med 1975; 82 (4): 460-465.
19. Zachee P, Van Hove L, Hauglustaine D et al. Effect of recombinant human erythropoietin on reticulocyte age in hemodialysis patients. Nephron 1992; 62: 366-367.
20. Eschbach JW, Adamson J. Recombinant human erythropoietin: Implications for nephrology. Am J Kidney Dis 1988; 11(3): 203-209.
21. Djordjevic V, Djordjevic
VB
, Pejovic M et al. Antioxidant enzymes in erythrocytes of patients on maintenance hemodialysis treated with human recombinant erythropoietin (rHuEPO). Bio News ScientifıcNR1993;30:3-33.
22. Turi S, Nemeth I, Varga I. The effect of erythropoietin on the cellular defence mechanism of red blood cells in children with chronic renal failure. Pediatr Nephrol 1992;
6(6): 536-541.
23. Luciak M, Kedziora J, Blaszczyk J et al. Does recombinant human erythropoietin therapy modify intradialytic erythrocyte oxidative metabolism in chronic uremic patients. Bio News Scientific 1993; 28(6): 31.
24. Çavdar C, Çamsan T, Semin I et al. Lipid peroxidation and antioxidant activity in chronic haemodialysis patients treated with recombinant human erythropoietin. Scand J Urol Nephrol 1997; 31: 000 - 000 (Basımda)
25. Zachee P, Ferrant A, Daelemans R et al. Oxidative injury to erythrocytes, cell rigidity and splenic hemolysis in hemodialyzed patients before and during erythropoietin
treatment. Nephron 1993; 65: 288-293.
105

Thank you for copying data from http://www.arastirmax.com